In fi­nal days at Mer­ck, Roger Perl­mut­ter bets big on a lit­tle-known Covid-19 treat­ment

Roger Perl­mut­ter is spend­ing his last days at Mer­ck, well, spend­ing.

Two weeks af­ter snap­ping up the an­ti­body-drug con­ju­gate biotech Velos­Bio for $2.75 bil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.